A Phase 1 study of IMGN632, a CD123-targeted ADC for the treatment of hematological malignancies.

Trial Profile

A Phase 1 study of IMGN632, a CD123-targeted ADC for the treatment of hematological malignancies.

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs IMGN-632 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2017 According to an ImmunoGen media release, the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application and company plans to open study to enrollment before the end of the year.
    • 01 Sep 2017 New trial record
    • 29 Aug 2017 According Jazz Pharmaceuticals plc media release, ImmunoGen expects to file an investigational new drug application (IND) for IMGN632 this quarter and planning to enroll first patient before the end of the 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top